Hecht walks through studies raising concerns that Ozempic and Wegovy may be tied to a rare optic nerve problem that can affect vision.
Recap by typeshit. Post by @dr.alexahecht on Instagram.
The actor backed Ozempic in an interview while saying exercise has no shortcut. Doctors break down whether his advice holds up.
A BusinessWorld piece on FDA worries about unapproved GLP-1 weight loss drugs, including retatrutide, which is still in trials. Few details were available.
After his appetite disappeared on tirzepatide, Krasno talks with the Your Best Shot author about food and why scale weight can mask muscle, bone and testosterone loss.
BioPharma Dive reports the recall adds to safety worries about knockoff weight loss drugs, which stay popular despite FDA warnings and pressure from Lilly and Novo.
A Facebook user posts a side-by-side from six years ago and now, crediting a weight loss journey that includes the Wegovy pill.
Maqubela's list of 2025 brand revenues puts Ozempic third at $19.2b, ahead of Dupixent and Skyrizi.
Loading…